Trials / Withdrawn
WithdrawnNCT05405192
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dostarlimab | First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2022-06-06
- Last updated
- 2023-02-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05405192. Inclusion in this directory is not an endorsement.